20 November 2025
\n \n \n \nAbbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments.
\n \n\n \n \n19 November 2025
\n \n \n \nPrior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.
\n \n\n \n \n18 November 2025
\n \n \n \nOchre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, today announced the successful completion of the research phase of its collaboration with GSK, delivering two comprehensive functional genomics and single-cell human liver datasets.
\n \n\n \n \n12 November 2025
\n \n \n \nThe Composition of Matter patent covers the Company\u2019s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio.
\n \n\n \n \n6 November 2025
\n \n \n \nGroundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside\r\nliving cells at base pair resolution for the first time, pioneering a new approach to identify new drug\r\ntargets from human genetics.
\n \n\n \n \n4 November 2025
\n \n \n \nEnara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens\u00ae and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX\u2122 as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.
\n \n\n \n \n31 October 2025
\n \n \n \nThe University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.
\n \n\n \n \n30 October 2025
\n \n \n \nLeveraging deep scientific and clinical expertise in MPNs, the company aims to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells. Progress is being made with AT-01, a first-in-class antibody-drug conjugate (ADC) program, which has strong preclinical validation and is advancing toward IND/CTA-enabling studies anticipated to start in the first half of 2026. Additionally, AT-02 expands the ADC portfolio by targeting mutant CALR, a key driver mutation in MPNs. The leadership and board have been strengthened with the appointments of Dr. Rohit Batta as CEO and Mike Grey as Chair.
\n \n\n \n \n23 October 2025
\n \n \n \nMediMabBio has successfully raised KRW 25.6B (USD $17M) in its Series B financing round. The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.
\n \n\n \n \n12 October 2025
\n \n \n \nMediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.
\n \n\n \n \n6 October 2025
\n \n \n \nDr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.
\n \n\n \n \n23 September 2025
\n \n \n \n53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity
\n \n\n \n \n23 September 2025
\n \n \n \nPepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.
\n \n\n \n \n17 September 2025
\n \n \n \nFirst phase completed a year earlier than typical industry timelines
\n \n\n \n \n8 September 2025
\n \n \n \nFollows successful completion of pre-clinical activities by Alchemab as part of an earlier licensing deal with Eli Lilly and Company for ATLX-1282. Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors.
\n \n\n \n \n1 September 2025
\n \n \n \nCollaboration leverages OMass\u2019 OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.
\n \n\n \n \n25 August 2025
\n \n \n \nOXFORD UK: Moa Technology today announces its discovery of chemistries which could become an entirely new category of products to help farmers protect their harvests more safely, sustainably and effectively.
\n \n\n \n \n6 August 2025
\n \n \n \nTheolytics has created an extensive proprietary library of oncolytic viruses (viruses that kill cancer cells) to harness their potential to safely target and destroy tumour cells while leaving healthy cells intact.
\n \n\n \n \n5 August 2025
\n \n \n \nOMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.
\n \n\n \n \n20 July 2025
\n \n \n \nJLL announced today that it has completed a sublease for growing U.K.-based biotech company Ochre Bio at 430 East 29th St. within the Alexandria Center\u00ae for Life Science \u2013 New York City.
\n \n\n \n \n